


Bridging with Characterisation



Pfizer GLOBAL SUPPLY


FACE is the bridge between the world of API and DP, facilitated by material characteristics.



Note: Equipment can be used in different work area, but one shown is where there has been greatest application

Technologies for Chemical

Matrix Elucidation



Toolbox for Liquid and Suspension Formulations



Sympatec Laser Diffraction

•Particle size for liquid dispersions with focused measurement range

Pfizer GLOBAL SUPPLY

Pfizer GLOBAL SUPPLY



•Used to determine particle morphology

•Structural information by phase contrast microscopy

Optical Microscopy

Scanning Electron Microscopy

•Particulate matter or particle morphology •Surface characteristics



Rheology

Rheology for structural informationStability of a liquid product



Malvern Laser Diffraction

 Particle size for liquid dispersions with wide measurement range

Image Analysis

•Optical particle sizing technique



Rheolaser

For sedimentation and structural properties
Stability of a suspension



Turbiscan

•De-stabilisation of a network structure i.e. Sedimentation or creaming



Tensiometer

•Wetability of powder beds for wet granulation and dissolution issues



Zeta-Sizer

Zeta potentialSizing




Roots in Drug Product Characterisation

Using Chemical Images to Understand Product Performance



Matrix Elucidation Providing Insights into Slow Dissolution


Pfizer GLOBAL SUPPLY




Focuses Investigation Team of Raw Material Variation or

Excipient Variability

- CoA comparison of Raw Materials Identified no variations
- Characterisation Identified difference in hydration state of magnesium stearate
- Now known as a critical attribute for this product






Pfizer GLOBAL SUPPLY


Pfizer GLOBAL SUPPL

Drug Product Issue – Blend,... Uniformity

- Flow issues during DP manufacture resulted in blend uniformity issues following an API source change.
 - API from new supplier had passed all specifications




Characterisation Studies identify new API has a greater proportion of fines (<10 μm) which results in different cohesion properties.





Supporting DP Trials


Trial Batch with New API Source



Commercial Batch with New API Source








Pfizer GLOBAL SUPPLY

Pfizer GLOBAL SUPPLY


Inhomogeneity in Drug Product

- Following a site change inhomogeneity observed in drug product results.
- Processing equipment and parameters had been comparable.
- Raw materials all meet CoA.



Excipient Evaluation

- Full characterisation of 15+ components identified differences in particle size and chemical content of some raw materials
 - Issues linked to particle size differences
- Utilisation of raw materials from initial DP site gave rise to good homogeneity










Excipient Identification

- Notified that current raw material supplier will be ceasing manufacture.
- Understanding of this material and its attributes in DP deemed a necessary for low risk change.
 - Material from 4 alternate suppliers sourced for comparison.



Assessing PSD






Pfizer GLOBAL SUPPLY


Pfizer GLOBAL SUPPL

Alternate sources offer very different PSD from current source

Evaluation of Physico-Chemical Properties

• NIR and PXRD identify chemical variations in one alternative source, which by EGA is shown to be a anhydrous form.







Pfizer GLOBAL SUPPLY

Pfizer GLOBAL SUPPLY

Sample	% Mass lost (30-145°C)
M Alternative	2.31
Current	0.83
P Alternative	0.77
F Alternative	0.60



Viscosity of Lab Scale Formulations






Suspension Properties






Pfizer GLOBAL SUPPLY


Variation in Settled Bed Height




API Morphology


Pfizer GLOBAL SUPPLY









Size and Flow Attributes



Surface Properties Drive Sedimentation


• Issues lots have higher surface heterogeneity, which could be driving the stability of the suspension of the final drug product.






Understand Root Cause of Dissolution Performance Variability using Imaging Methods

• Five capsule lots with variable dissolution performance



Only excipient with variation through characterisation testing was magnesium stearate




NIR Chemical Images Identify No significant Variation

Pfizer GLOBAL SUPPL


Pfizer GLOBAL SUPPLY


Looking at the Capsule Contents

• X-ray images reveal variation in powder packing



Crude Classification of Powder State in Capsules (Compaction).





Pfizer GLOBAL SUPPL

compaction behaviour of capsule contents were evaluated

Pizer


GLOBAL SUPPL


Understanding Dissolution Performance of Capsule Product

 To build understanding of prediction ability of X-ray images, a 'calibration set' was generated using different tamping pin settings.



Greyscale Histograms were generated from X-ray Images






Work completed in collaboration with Professor Ryan Gosling, University of Sherbrooke

Understanding Dissolution Performance of Capsule Product

A 2-class SIMCA model was created using low-pressure and high-pressure capsules.



Chemometrics and Classification Success

Blue and Cyan = Acceptable Red and Yellow = Unacceptable 99% Confidence Limit Shown in Red

- 6 Rotational Angles used
 - to represent a capsule.

Pfizer GLOBAL SUPPLY

Pfizer GLOBAL SUPPLY

- Classification Success rates of 97.5% and 95% for unagglomerated and agglomerated validation sets.
- X-ray images coupled with greyscale histograms and chemometrics can be used to classify the performance of this product.

Low Pressure Plot

High Pressure Plot



Solid State Characterisation for Understanding Impurity Levels






Pfizer GLOBAL SUPPL

Question: Why are levels of 1 imp higher at one DP site?


- Both sites use same API source
- Chemical Images reveal difference in one excipient.





Comparison of Excipient Properties


GLOBAL SUPPLY

Pfizer GLOBAL SUPPLY










How does this impact Tablet Stability Performance?






Implemented Learnings





Building Learnings into Workflow for API-DP



Leveraging API-DP Interface

- By building understanding of material characteristics (be that API, excipients or drug product) understanding of product attributes are increased.
- Leveraging this knowledge in combination with that of API and Drug Product enables more robust drug products.
- It also enables low risk transfers and sourcing decisions.

